KnowraRituximabLinked fromLinked fromThe 19 pages that link to Rituximab, each with the reason it gives.All 19Broader topic 4Related 11Compared with 4Monoclonal antibodyBroader topic: It exemplifies treatment through selective targeting of a cell-surface protein.B cellRelated: It treats some B-cell cancers and autoimmune diseases by depleting CD20-positive cells.VasculitisRelated: It is used to treat certain severe or relapsing vasculitis syndromes.Granulomatosis with polyangiitisRelated: It is used with glucocorticoids to induce or maintain remission in many patients.Intravenous immunoglobulinCompared with: It suppresses a source of antibodies rather than supplying pooled antibodies.Antibody-dependent cellular cytotoxicityBroader topic: Its antitumor activity can include natural killer cell-mediated ADCC against CD20-positive cells.AzathioprineCompared with: It suppresses immunity by targeting a defined cell population rather than broadly disrupting purine metabolism.Thrombotic thrombocytopenic purpuraRelated: It can suppress anti-ADAMTS13 autoantibodies and reduce relapse risk.CyclophosphamideCompared with: For some autoimmune diseases, targeted B-cell depletion offers an alternative to broad cytotoxic immunosuppression.Autoimmune hemolytic anemiaRelated: It can treat autoimmune hemolytic anemia that persists or returns after initial therapy.Microscopic polyangiitisRelated: It is an induction and maintenance option for many patients with severe ANCA-associated vasculitis.César MilsteinBroader topic: Its development illustrates the clinical reach of monoclonal antibody technology.Chronic inflammatory demyelinating polyneuropathyRelated: It may be considered in selected difficult cases, especially when nodal antibodies are found.Neuromyelitis optica spectrum disorderRelated: B-cell depletion is used to reduce relapses and antibody-driven inflammation.Castleman diseaseRelated: It is used in some HHV-8-associated cases to reduce infected B cells.OcrelizumabCompared with: It targets the same antigen but has a different antibody structure and is not specifically approved for multiple sclerosis.Stiff-person syndromeRelated: It has been tried as immune-directed therapy, but benefits in stiff-person syndrome are inconsistent.Anti-NMDA receptor encephalitisRelated: It is used as second-line immunotherapy when initial treatment does not control the disease.Therapeutic antibodyBroader topic: It exemplifies antibody-mediated depletion of a disease-associated cell population.
KnowraRituximabLinked fromLinked fromThe 19 pages that link to Rituximab, each with the reason it gives.All 19Broader topic 4Related 11Compared with 4Monoclonal antibodyBroader topic: It exemplifies treatment through selective targeting of a cell-surface protein.B cellRelated: It treats some B-cell cancers and autoimmune diseases by depleting CD20-positive cells.VasculitisRelated: It is used to treat certain severe or relapsing vasculitis syndromes.Granulomatosis with polyangiitisRelated: It is used with glucocorticoids to induce or maintain remission in many patients.Intravenous immunoglobulinCompared with: It suppresses a source of antibodies rather than supplying pooled antibodies.Antibody-dependent cellular cytotoxicityBroader topic: Its antitumor activity can include natural killer cell-mediated ADCC against CD20-positive cells.AzathioprineCompared with: It suppresses immunity by targeting a defined cell population rather than broadly disrupting purine metabolism.Thrombotic thrombocytopenic purpuraRelated: It can suppress anti-ADAMTS13 autoantibodies and reduce relapse risk.CyclophosphamideCompared with: For some autoimmune diseases, targeted B-cell depletion offers an alternative to broad cytotoxic immunosuppression.Autoimmune hemolytic anemiaRelated: It can treat autoimmune hemolytic anemia that persists or returns after initial therapy.Microscopic polyangiitisRelated: It is an induction and maintenance option for many patients with severe ANCA-associated vasculitis.César MilsteinBroader topic: Its development illustrates the clinical reach of monoclonal antibody technology.Chronic inflammatory demyelinating polyneuropathyRelated: It may be considered in selected difficult cases, especially when nodal antibodies are found.Neuromyelitis optica spectrum disorderRelated: B-cell depletion is used to reduce relapses and antibody-driven inflammation.Castleman diseaseRelated: It is used in some HHV-8-associated cases to reduce infected B cells.OcrelizumabCompared with: It targets the same antigen but has a different antibody structure and is not specifically approved for multiple sclerosis.Stiff-person syndromeRelated: It has been tried as immune-directed therapy, but benefits in stiff-person syndrome are inconsistent.Anti-NMDA receptor encephalitisRelated: It is used as second-line immunotherapy when initial treatment does not control the disease.Therapeutic antibodyBroader topic: It exemplifies antibody-mediated depletion of a disease-associated cell population.